Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00
CLDI.WS
CLDI.WS was delisted on the 17th of October, 2024.
22 hedge funds and large institutions have $5.93M invested in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in 2021 Q4 according to their latest regulatory filings, with 22 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$558K |
| 2 |
AMH
Apollo Management Holdings
New York
|
+$558K |
| 3 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$419K |
| 4 |
FC
Finepoint Capital
Boston,
Massachusetts
|
+$370K |
| 5 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
+$355K |
Top Sellers
CLDI.WS Hedge Fund Activity: Q4 2021 in Review
22 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) for Q4 2021, worth a combined $5.93M.
Buyers outnumbered sellers: 22 funds opened new CLDI.WS positions and 0 closed out — a net gain of 22 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Woodline Partners, opening a new position worth an estimated $558K.
- 22 institutional investors held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) as of Q4 2021, up from 0 in Q3 2021.
- Funds reported $5.93M of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 stock for Q4 2021.
- 22 funds opened new Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 positions in Q4 2021 and 0 closed out, a net change of +22 holders.
- The largest Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 buyer in Q4 2021 was Woodline Partners, an estimated $558K added.
Based on aggregated 13F filings for Q4 2021.